Blog
RSS FeedPosted by Michael Wonder on 07 Jun 2026
Vyloy, Fintepla and Rybrevant move closer to reimbursement after passing HIRA review
5 June 2026 - Several new therapies for serious and rare diseases have moved a step closer to receiving national ...
Posted by Michael Wonder on 05 Jun 2026
First new NHS treatment in over 20 years recommended for women with resistant ovarian cancer
4 June 2026 - The treatment uses a targeted therapy that seeks out a specific protein found on the surface of ...
Posted by Michael Wonder on 05 Jun 2026
US FDA approves FoundationOne CDx as a companion diagnostic for Itovebi (inavolisib) to identify patients with hormone receptor positive, HER2 negative breast cancer with a PIK3CA mutation
2 June 2026 - Foundation Medicine today announced that it has received approval from the US FDA for FoundationOne CDx ...
Posted by Michael Wonder on 05 Jun 2026
J&J Innovative Medicine Korea wins reimbursement for Darzalex SC regimen in newly diagnosed AL amyloidosis
4 June 2026 - Johnson & Johnson Innovative Medicine Korea said Darzalex subcutaneous injection-based quadruple regimen has received reimbursement in ...
Posted by Michael Wonder on 04 Jun 2026
Verastem Oncology announces US FDA fast track designation for VS-7375, an oral and potential best in class investigational KRAS G12D (ON/OFF) inhibitor for the treatment of KRAS G12D mutated locally advanced or metastatic non-small cell lung cancer
3 June 2026 - Verastem Oncology today announced that the US FDA has granted hast track designation to VS-7375, an oral ...
Posted by Michael Wonder on 02 Jun 2026
FDA accepts new drug application for Roche’s giredestrant in oestrogen receptor positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
2 June 2026 - Roche announced today that the US FDA has accepted the company’s new drug application under priority review ...
Posted by Michael Wonder on 02 Jun 2026
GSK secures Omjjara reimbursement in Korea, expanding access for myelofibrosis patients
1 June 2026 - GSK Korea said Monday that its myelofibrosis treatment Omjjara (momelotinib hydrochloride hydrate) has been granted reimbursement ...
Posted by Michael Wonder on 01 Jun 2026
Nouscom receives US FDA fast track designation for NOUS-209, a novel immunotherapy for the prevention of Lynch syndrome-associated cancers
1 June 2026 - Nouscom today announced that the US FDA has granted fast track designation to NOUS-209 for the prevention ...
Posted by Michael Wonder on 01 Jun 2026
Bristol Myers Squibb announces Opdivo (nivolumab) in combination with AVD receives expanded EU label with approval in frontline advanced classical Hodgkin lymphoma
1 June 2026 - Bristol Myers Squibb today announced that the European Commission has approved Opdivo (nivolumab) in combination with ...
Posted by Michael Wonder on 01 Jun 2026
BMS Korea expands Pomalyst reimbursement to secpnd-line multiple myeloma treatment
29 May 2026 - Bristol Myers Squibb Korea said its Pomalyst (pomalidomide)-based triple therapy will become reimbursable from 1 June ...
Posted by Michael Wonder on 01 Jun 2026
Expanded listing to save leukaemia patients $35.5 million a year
1 June 2026 - Eligible patients with leukaemia will have access to $25 scripts for two new treatments following their ...
Posted by Michael Wonder on 31 May 2026
FDA grants breakthrough therapy designation for calderasib (MK-1084), an investigational KRAS G12C inhibitor, for certain patients with newly diagnosed metastatic KRAS G12C mutant non-small cell lung cancer
29 May 2026 - First breakthrough therapy designation for calderasib, supported by positive data from the Phase 1 KANDLELIT-001 trial. ...
Posted by Michael Wonder on 29 May 2026
BeOne Medicines receives positive reimbursement recommendations from CDA-AMC and INESSS for Tevimbra in first-line nasopharyngeal carcinoma
28 May 2026 - BeOne Medicines today announced that Canada's Drug Agency and the Institut national d'excellence en santé et ...
Posted by Michael Wonder on 29 May 2026
Imfinzi approved in the US in first and only immunotherapy combination for patients with BCG naïve, high risk non-muscle-invasive bladder cancer
28 May 2026 - Based on POTOMAC Phase 3 trial results which showed a 32% reduction in the risk of ...
Posted by Michael Wonder on 29 May 2026
AbbVie’s Elahere clears first reimbursement hurdle for platinum-resistant ovarian cancer in Korea
28 May 2026 - AbbVie’s ovarian cancer drug Elahere has cleared its first hurdle toward reimbursement coverage in Korea, potentially ...